About Ross Merkin, MD

Ross Merkin, MD is a medical oncologist in the Center for Head and Neck Cancers at Mass General Cancer Center. He is also an Instructor in Medicine at Harvard Medical School.

Dr. Merkin graduated magna cum laude from Northeastern University in Boston, Massachusetts in 2011 with a BS in biology. He then earned his MD degree from SUNY Stony Brook University School of Medicine in Stony Brook, New York in 2016. During medical school he was inducted into Alpha Omega Alpha (AΩA), the medical honors society for outstanding achievement and earned accolades for his translational research. He completed his internal medicine residency at Montefiore Medical Center (Moses and Weiler Campuses) in Bronx, NY in 2019 and was subsequently invited to serve as Chief Resident, which he completed in 2020. He went on to complete his hematology/oncology training at Yale University and Yale Cancer Center / Yale New Haven Hospital in New Haven, CT in 2023. He joined Mass General Cancer Center / Harvard Medical School in 2023 as a medical oncologist.

Dr. Merkin’s clinical interests are in cancers of the head and neck, with a focus on mucosal squamous cell carcinoma, HPV-related head and neck cancer, salivary gland cancer, and advanced thyroid cancer. He also works with a multidisciplinary team to deliver care to patients with complications of immunotherapy.

Departments, Centers, & Programs:

Clinical Interests:




Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130

Medical Education

  • MD, Renaissance School of Medicine at Stony Brook University
  • Residency, Albert Einstein College of Medicine
  • Residency, Albert Einstein College of Medicine
  • Fellowship, Yale Cancer Center

American Board Certifications

  • Hematology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Merkin's clinical and translational research interests are focused on discovering better treatments for head and neck cancers. He also studies complications of immune checkpoint inhibitors, also called immune-related adverse events (irAEs). He takes a collaborative approach to discovering novel approaches aimed at improving care for patients with head and neck cancer or irAEs.


Reviews: Comments and Ratings